Business
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
About this update from Edesa Biotech, Inc.
[{"type":"text","content":"Oral presentation at ERA Congress, the flagship European nephrology meetingCompany expects to present additional data TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it will present data on paridiprubart, its first-in-class anti-TLR4 antibody, at the 63rd European Renal Association (ERA) Congress, to be held June 3 – 6, 2026, in Glasgow, Scotland. The ERA Congress is one of the world's leading nephrology meetings, convening clinicians and researchers focused on kidney disease. Edesa's accepted oral presentation will feature exploratory data and analysis from the company's study of paridiprubart in patients with respiratory distress who also experienced acute kidney injury, a high-mortality complication that currently lacks approved, targeted therapies. Edesa also plans to present additional data at the ERA Congress to further support the potential of paridiprubart as a treatment for AKI. \"The ERA Congress represents a critical platform to advance awareness of paridiprubart's potential in AKI—a disease with profound unmet need and limited therapeutic options,” said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. “Our Phase 3 data demonstrate a consistent, statistically significant reduction in mortality in AKI patients, grounded in a well-established mechanism. We look forward to sharing these findings with the nephrology community in Glasgow and presenting additional analysis that further support the potential of paridiprubart as a targeted treatment for this devastating condition.\" Edesa’s oral presentation, titled Exploratory Analysis of Paridiprubart, an Anti-TLR4 Antibody, in Patients with Acute Kidney Injury and Respiratory Distress, is scheduled for June 5, 2026 at 4:30 pm local time. Related materials will be posted to the Events section of the Edesa Biotech website during the conference. About Paridiprubart Paridiprubart is a first-in-class anti-TLR4 (Toll-like Receptor 4) monoclonal antibody designed to modulate the body's immune response. By selectively inhibiting TLR4, paridiprubart dampens the hyperinflammatory cascade implicated in Acute Respiratory Distress Syndrome (ARDS), AKI, sepsis, pneumonia, and other critical inflammatory condition...